| 國立成功大學 |
2002-07-29 |
Hepa-1 小鼠細胞蛋白質體如何受2 3 7 8-四氯戴奧辛影響
|
洪千雯; Hung, Chien-Wen |
| 國立臺灣大學 |
2015 |
Heparan Sulfate Modulates Neutrophil and Endothelial Function in Antibacterial Innate Immunity
|
Xu, Ding; Olson, Joshua; Cole, Jason N.; van Wijk, Xander M.; Brinkmann, Volker; Zychlinsky, Arturo; Nizet, Victor; Esko, Jeffrey D.; Chang, Yung-Chi; 張永祺 |
| 臺大學術典藏 |
2000 |
Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7)
|
Wei-Hsuan Yu;Woessner Jr. J.F.; WEI-HSUAN YU; Woessner Jr. J.F. |
| 國立成功大學 |
2009-05 |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu, Chun-Jen; Lee, Po-Huang; Lin, Deng-Yn; Wu, Cheng-Chung; Jeng, Long-Bin; Lin, Pin-Wen; Mok, King-Tong; Lee, Wei-Chen; Yeh, Hong-Zen; Ho, Ming-Chih; Yang, Sheng-Shun; Lee, Ching-Chih; Yu, Ming-Chin; Hu, Rey-Heng; Peng, Cheng-Yuan; Lai, Kuan-Lang; Chang, Stanley Shi-Chung; Chen, Pei-Jer |
| 國立臺灣大學 |
2009 |
Heparanase Inhibitor Pi-88 as Adjuvant Therapy for Hepatocellular Carcinoma after Curative Resection: A Randomized Phase Ii Trial for Safety and Optimal Dosage
|
劉俊人; 李伯皇; 胡瑞恆; 吳誠中; 鄭隆賓; 林炳文; 莫景棠; 葉宏仁; 何明志; 楊勝舜; 陳培哲; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
| 中國醫藥大學 |
2009-02 |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
劉俊人(Chun-Jen Liu); 李伯皇(Po-Huang Lee); 林燈寅(Deng-Yn Lin); 吳誠中(Cheng-Chung Wu); 鄭隆賓(Long-Bin Jeng); 林炳文(Pin-Wen Lin); 莫景棠(King-Tong Mok); 李威震(Wei-Chen Lee); 葉宏仁(Hong-Zen Yeh); 何明志(Ming-Chih Ho); (Sheng-Shun Yang); 李靜枝(Ching-Chih Lee); 游明晉(Ming-Chin Yu); 胡瑞恆(Rey-Heng Hu); 彭成元(Cheng-Yuan Peng); (Kuan-Lang Lai); (Stanley Shi-Chung Chang); 陳培哲(Pei-Jer Chen)* |
| 臺大學術典藏 |
2018-09-10T07:26:51Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu, C.-J. and Lee, P.-H. and Lin, D.-Y. and Wu, C.-C. and Jeng, L.-B. and Lin, P.-W. and Mok, K.-T. and Lee, W.-C. and Yeh, H.-Z. and Ho, M.-C. and Yang, S.-S. and Lee, C.-C. and Yu, M.-C. and Hu, R.-H. and Peng, C.-Y. and Lai, K.-L. and Chang, S.S.-C. and Chen, P.-J.; 劉俊人;李伯皇;胡瑞恆;吳誠中;鄭隆賓;林炳文;莫景棠;葉宏仁;何明志;楊勝舜;陳培哲; LIU, CHUN-JEN;LEE, PO-HUANG;HU, REY-HENG;WU, CHENG-CHUNG;JENG, LONG-BIN;LIN, PIN-WEN;MOK, KING-TONG;YEH, HONG-ZEN;HO, MING-CHIH;YANG, SHENG-SHUN;CHEN, PEI-JER; MING-CHIH HO; PO-HUANG LEE; CHUN-JEN LIU; PEI-JER CHEN; REY-HENG HU; LIU, CHUN-JEN; LEE, PO-HUANG; HU, REY-HENG; WU, CHENG-CHUNG; JENG, LONG-BIN; LIN, PIN-WEN; MOK, KING-TONG; YEH, HONG-ZEN; HO, MING-CHIH; YANG, SHENG-SHUN; CHEN, PEI-JER |
| 臺大學術典藏 |
2020-02-19T09:33:57Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2020-11-19T03:19:55Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; PO-HUANG LEE; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 臺大學術典藏 |
2021-07-03T03:34:53Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
Liu C.-J.; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN |
| 臺大學術典藏 |
2022-01-24T09:32:03Z |
Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage
|
CHUN-JEN LIU; Lee P.-H.; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; Ho M.-C.; Yang S.-S.; Lee C.-C.; Yu M.-C.; Hu R.-H.; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; Chen P.-J. |
| 元培科技大學 |
2002 |
Heparin binding stabilizes the membrane-bound form of cobra cardiotoxin.
|
Sue SC; Chien KY; Huang WN; Abraham JK; Chen KM; Wu WG. |
| 大葉大學 |
2015-01 |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
WY, Liao;CC, Ho;HH, Hou;TH, Hsu;Tsai, Meng-Feng;KY, Chen;HY, Chen;YC, Lee;CJ, Yu;CH, Lee;PC, Yang |
| 國立臺灣大學 |
2015 |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao, Wei-Yu; Ho, Chao-Chi; Hou, Hsin-Han; Hsu, Tsi-Hsuan; Tsai, Meng-Feng; Chen, Kuan-Yu; Chen, Hsuan-Yu; Lee, Yung-Chie; Yu, Chong-Jen; Lee, Chau-Hwang; Yang, Pan-Chyr; 楊泮池; 廖唯昱; 陳冠宇; 余忠仁; 何肇基; 李元麒 |
| 臺大學術典藏 |
2018-09-10T15:17:21Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao, W.-Y. and Ho, C.-C. and Hou, H.-H. and Hsu, T.-H. and Tsai, M.-F. and Chen, K.-Y. and Chen, H.-Y. and Lee, Y.-C. and Yu, C.-J. and Lee, C.-H. and Yang, P.-C.; Liao, Wei-Yu;Ho, Chao-Chi;Hou, Hsin-Han;Hsu, Tsi-Hsuan;Tsai, Meng-Feng;Chen, Kuan-Yu;Chen, Hsuan-Yu;Lee, Yung-Chie;Yu, Chong-Jen;Lee, Chau-Hwang;Yang, Pan-Chyr; 楊泮池;廖唯昱;陳冠宇;余忠仁;何肇基;李元麒; 楊泮池;廖唯昱;陳冠宇;余忠仁;何肇基;李元麒; WEI-YU LIAO; Liao, Wei-Yu; Ho, Chao-Chi; CHONG-JEN YU; Hou, Hsin-Han; CHAO-CHI HO; Chan, Ding-Cheng; Hsu, Tsi-Hsuan; Tsai, Meng-Feng; Chen, Kuan-Yu; Chen, Hsuan-Yu; Lee, Yung-Chie; Yu, Chong-Jen; Lee, Chau-Hwang; Yang, Pan-Chyr |
| 臺大學術典藏 |
2015 |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Yang P.-C.; Lee C.-H.; Yu C.-J.; Lee Y.-C.; Chen H.-Y.; Liao W.-Y.;Ho C.-C.;Hsin-Han Hou;Hsu T.-H.;Tsai M.-F.;Chen K.-Y.;Chen H.-Y.;Lee Y.-C.;Yu C.-J.;Lee C.-H.;Yang P.-C.; Liao W.-Y.; Ho C.-C.; HSIN-HAN HOU; Hsu T.-H.; Tsai M.-F.; Chen K.-Y. |
| 臺大學術典藏 |
2020-07-21T06:09:12Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Yang P.-C.; Lee C.-H.; Yu C.-J.; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y.; Chen H.-Y.; Lee Y.-C.; Ho C.-C.; WEI-YU LIAO |
| 臺大學術典藏 |
2020-07-21T06:46:27Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Yu C.-J.; Lee C.-H.; Yang P.-C.; Lee Y.-C.; Chen H.-Y.; Liao W.-Y.; CHAO-CHI HO; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y. |
| 臺大學術典藏 |
2020-12-02T02:33:34Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao W.-Y.; Ho C.-C.; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y.; Chen H.-Y.; Lee Y.-C.; Yu C.-J.; Lee C.-H.; Pan-Chyr Yang; Liao W.-Y.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2021-04-29T02:38:37Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Anonymous |
| 臺大學術典藏 |
2021-04-29T05:09:04Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao W.-Y.; Ho C.-C.; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; KUAN-YU CHEN; Chen H.-Y.; Lee Y.-C.; Yu C.-J.; Lee C.-H.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:01:43Z |
Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer
|
Liao W.-Y.; Ho C.-C.; Hou H.-H.; Hsu T.-H.; Tsai M.-F.; Chen K.-Y.; Chen H.-Y.; Lee Y.-C.; CHONG-JEN YU; Lee C.-H.; Yang P.-C. |
| 慈濟大學 |
2012 |
Heparin cofactor II 蛋白與丙型肝炎病毒的交互作用
|
黃玉玲 |
| 臺大學術典藏 |
2018-09-10T07:12:05Z |
Heparin immobilization onto polyurethane surfaces and their characterization
|
Wang, S.-S. and Lin, Y.-S. and Chou, N.-K. and Chu, S.-H.; Nai-Kuan Chou |
| 臺大學術典藏 |
2020-03-05T08:38:35Z |
Heparin immobilization onto polyurethane surfaces and their characterization
|
Shoei-Shen Wang;Lin Y.-S.;Chou N.-K.;Chu S.-H.; SHOEI-SHEN WANG; Lin Y.-S.; Chou N.-K.; Chu S.-H. |
